ArticleJACC. Asia2026

Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension: Design of the Randomized, Double-Blind, Placebo-Controlled ALEPH Trial.

Jun-Yan Kan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.